The Scottish Medicines Consortium (SMC) has ruled Idefirix (imlifidase) clinically and cost-effective in highly sensitised adult patients prior to kidney transplant from a deceased donor.  The recommendation, which follows a positive ruling by the National Institute of Health and Care Excellence (NICE), marks an important milestone as highly sensitised patients are currently highly unlikely to […]